Treace Medical Concepts Q3 2026 Results: Net Loss of $12.6M, Loss Narrows
Treace Medical Concepts, Inc. filed this Form 10-Q for the quarter ended September 30, 2026, reporting 65,559,597 shares of common stock outstanding as of October 30, 2026. The company is focused on managing expenses to offset revenue growth shifts and navigating competition in the bunion surgery market, including its flagship Lapiplasty system.
- Key figure
- Net loss $12.6M